Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Leadership Team For European Biosimilars Group

This article was originally published in Scrip

Executive Summary

The European Biosimilar medicines Group (EBG), part of the European Generic and Biosimilar Medicines Association (EGA), has appointed a new leadership team, with Carol Lynch chairing the overall group and Klaus Martin heading up the EBG's market access group. Lynch, who is global head of biopharmaceuticals and oncology injectables at Sandoz, previously held commercial and development leadership positions at Novartis Pharmaceuticals. Martin is senior director and chief science officer at Polpharma Biologics, leading global late-stage development, portfolio management and strategic marketing and medical affairs, and has worked in the biosimilars area since 2002. Ildiko Aradi of Gedeon Richter and Karl Heinz Emmert of Teva were re-elected vice-chairs of the EBG, while Dan Ionesco of Sandoz was appointed vice-chair of the market access group.

Advertisement
Advertisement
UsernamePublicRestriction

Register

SC064450

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel